Search clinical trials for: Durvalumab (MEDI4736)

Total 758 results

Memorial Sloan Kettering Cancer Center
Celgene Corporation

Withdrawn

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Solitary Bone Plasmacytoma

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Metastatic Colorectal Cancer

United States
University of Maryland, Baltimore

Withdrawn

Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598) (Panc-Durval+RT)

Metastatic Pancreas Cancer
Ottawa Hospital Research Institute
AstraZeneca; Hamilton Health Sciences Corporation; London Health Sciences Centre and other collaborators

Recruiting

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)

Bladder Cancer

Canada
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Yonsei University

Recruiting

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Potentially Resectable Stage II/IIIa NSCLC

Korea, Republic of
AstraZeneca

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Advanced Solid Tumours

United States
MedImmune LLC

Completed

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Cancer | Solid Tumors

United States, Spain
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Shadia Jalal, MD
AstraZeneca; MedImmune LLC; Big Ten Cancer Research Consortium

Completed

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Active, not recruiting

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Nonseminomatous Germ Cell Tumor | Seminoma | Germ Cell Tumor | Dysgerminoma | Pineal Germ Cell Tumor | Germinomatous Germ Cell Tumor

United States
Monika Joshi, MD
AstraZeneca

Active, not recruiting

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)

Urothelial Cancer

United States
Italian Network for Tumor Biotherapy Foundation
AstraZeneca

Unknown

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Peritoneal Mesothelioma | Pleural Mesothelioma

Italy
AstraZeneca

Active, not recruiting

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC)

Non-muscle-invasive Bladder Cancer

France, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
AstraZeneca

Completed

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States, United Kingdom
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
AstraZeneca

Completed

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain, Canada, Korea, Republic of, Netherlands, United States, Germany
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
MedImmune LLC

Terminated

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Cancer | Solid Tumors | CTCL

United States, France, Canada
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
Celgene

Active, not recruiting

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States, Italy, Canada, France, Germany, Netherlands, Spain
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
Do-Youn Oh
AstraZeneca

Active, not recruiting

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
MedImmune LLC

Completed

A Phase 1/2 Study to Evaluate MEDI4736

Advanced Solid Tumors

United States, Germany, Italy, United Kingdom, Belgium, Canada, Korea, Republic of, Taiwan, France
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

United States, Canada, France, Spain, Belgium, Czechia, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Australia, Germany, Georgia, Israel
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
MedImmune LLC

Active, not recruiting

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Italy, Spain, Taiwan, Korea, Republic of, China, Hong Kong, Japan, Singapore
AstraZeneca

Completed

Study of Tremelimumab in Patients With Advanced Solid Tumors

Pancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder Cancer

United States, Belgium, Korea, Republic of, Poland, Netherlands
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
German Breast Group
AstraZeneca; Celgene

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer

Germany
Yonsei University

Active, not recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Larynx | Stage II-IVB Operable HNSCC Oral Cavity | Hypopharynx | Oropharynx

Korea, Republic of
MedImmune LLC

Completed

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Japan
Asan Medical Center
Seoul National University Bundang Hospital; Hallym University Medical Center

Completed

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Metastatic Gastric Cancer

Korea, Republic of
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Cure Brain Cancer Foundation...

Completed

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Glioblastoma

United States, Australia
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria

Search clinical trials for: Durvalumab (MEDI4736)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations